Book contents
- Office Care of Women
- Office Care of Women
- Copyright page
- Dedication
- Contents
- Contributors
- Preface
- Section I Health promotion
- Section II Office interventions
- Section III Pregnancy
- Section IV Gynecology
- Section V Reproductive endocrinology and infertility
- Section VI Nongynecologic conditions
- Index
- References
Section V - Reproductive endocrinology and infertility
Published online by Cambridge University Press: 05 May 2016
Book contents
- Office Care of Women
- Office Care of Women
- Copyright page
- Dedication
- Contents
- Contributors
- Preface
- Section I Health promotion
- Section II Office interventions
- Section III Pregnancy
- Section IV Gynecology
- Section V Reproductive endocrinology and infertility
- Section VI Nongynecologic conditions
- Index
- References
- Type
- Chapter
- Information
- Office Care of Women , pp. 285 - 366Publisher: Cambridge University PressPrint publication year: 2016
References
References
Hughes, EG, Brennan, BG. Does cigarette smoking impair natural or assisted fecundity? Fertil Steril 1996; 66(5): 679–689.Google ScholarPubMed
Grodstein, F, Goldman, MB, Cramer, DW. Infertility in women and moderate alcohol use. Am J Public Health 1994; 84(9): 1429–1432.CrossRefGoogle ScholarPubMed
Zaadstra, BM, Looman, CW, te Velde, ER, et al. Moderate drinking: no impact on female fecundity. Fertil Steril 1994; 62(5): 948–954.CrossRefGoogle ScholarPubMed
Friedman, CI, Kim, MH. Obesity and its effect on reproductive function. Clin Obstet Gynecol 1985; 28(3): 645–663.CrossRefGoogle ScholarPubMed
Persani, L, Rossetti, R, Cacciatore, C. Genes involved in human premature ovarian failure. J Mol Endocrinol 2010; 45(5): 257–279.CrossRefGoogle ScholarPubMed
Hillis, SD, Joesoef, R, Marchbanks, PA, et al. Delayed care of pelvic inflammatory disease as a risk factor for impaired fertility. Am J Obstet Gynecol 1993; 168(5): 1503–1509.CrossRefGoogle ScholarPubMed
Bloomfield, HE, Olson, A, Greer, N, et al. Screening pelvic examinations in asymptomatic, average-risk adult women: an evidence report for a clinical practice guideline from the American College of Physicians. Ann Intern Med 2014; 161(1): 46–53.CrossRefGoogle ScholarPubMed
Fauser, BC, Tarlatzis, BC, Rebar, RW, et al. Consensus on women’s health aspects of polycystic ovary syndrome (PCOS): the Amsterdam ESHRE/ASRM-Sponsored 3rd PCOS Consensus Workshop Group. Fertil Steril 2012; 97(1): 28–38.CrossRefGoogle ScholarPubMed
Fumarola, A, Grani, G, Romanzi, D, et al. Thyroid function in infertile patients undergoing assisted reproduction. Am J Reprod Immunol 2013; 70(4): 336–341.CrossRefGoogle ScholarPubMed
Bahceci, M, Sismanoglu, A, Ulug, U. Comparison of cabergoline and bromocriptine in patients with asymptomatic incidental hyperprolactinemia undergoing ICSI-ET. Gynecol Endocrinol 2010; 26(7): 505–508.CrossRefGoogle ScholarPubMed
The ESHRE Capri Workshop. European Society for Human Reproduction and Embryology. Infertility revisited: the state of the art today and tomorrow. Hum Reprod 1996; 11(8): 1779–1807.CrossRefGoogle Scholar
World Health Organization. WHO laboratory manual for the examination and processing of human semen. 5th ed. Geneva: World Health Organization, 2010.Google Scholar
Schwartz, D, Laplanche, A, Jouannet, P, David, G. Within-subject variability of human semen in regard to sperm count, volume, total number of spermatozoa and length of abstinence. J Reprod Fertil 1979; 57(2): 391–395.CrossRefGoogle ScholarPubMed
Hjort, T. Antisperm antibodies. Antisperm antibodies and infertility: an unsolvable question? Hum Reprod 1999; 14(10): 2423–2426.CrossRefGoogle ScholarPubMed
Rotterdam ESHRE/ASRM-Sponsored PCOS Consensus Workshop Group. Revised 2003 consensus on diagnostic criteria and long-term health risks related to polycystic ovary syndrome. Fertil Steril 2004; 81(1): 19–25.CrossRefGoogle Scholar
Engmann, L, Maconochie, N, Sladkevicius, P, et al. The outcome of in-vitro fertilization treatment in women with sonographic evidence of polycystic ovarian morphology. Hum Reprod 1999; 14(1): 167–171.CrossRefGoogle ScholarPubMed
Zaidi, J, Jacobs, H, Campbell, S, Tan, SL. Blood flow changes in the ovarian and uterine arteries in women with polycystic ovary syndrome who respond to clomiphene citrate: correlation with serum hormone concentrations. Ultrasound Obstet Gynecol 1998; 12(3): 188–196.CrossRefGoogle ScholarPubMed
Zaidi, J, Campbell, S, Pittrof, R, et al. Ovarian stromal blood flow in women with polycystic ovaries–a possible new marker for diagnosis? Hum Reprod 1995; 10(8): 1992–1996.CrossRefGoogle ScholarPubMed
Sharara, F, Scott, RJ, Seifer, D. The detection of diminished ovarian reserve in infertile women. Am J Obstet Gynecol 1998; 179: 804–812.CrossRefGoogle ScholarPubMed
Engmann, L, Sladkevicius, P, Agrawal, R, et al. Value of ovarian stromal blood flow velocity measurement after pituitary suppression in the prediction of ovarian responsiveness and outcome of in vitro fertilization treatment. Fertil Steril 1999; 71(1): 22–29.CrossRefGoogle ScholarPubMed
Younis, JS, Haddad, S, Matilsky, M, et al. Undetectable basal ovarian stromal blood flow in infertile women is related to low ovarian reserve. Gynecol Endocrinol 2007; 23(5): 284–289.CrossRefGoogle ScholarPubMed
Hendricks, DJ, Mol, EW, Banksi, LF, et al. Antral follicle count in the prediction of poor ovarian response and pregnancy after invitro fertilisation; a meta analysis and comparison with basal follicle stimulating hormone level. Fertil Steril 2005; 83(2): 291–301.CrossRefGoogle Scholar
McIlveen, M, Skull, JE, Ledger, WL. Evaluation of the utility of multiple endocrine and ultrasound measures of ovarian reserve in the prediction of cycle cancellation in a high risk IVF population. Hum Reprod 2007; 22(3): 778–785.CrossRefGoogle Scholar
Nargund, G, Bourne, T, Doyle, P, et al. Ultrasound derived indices of follicular blood flow before HCG administration and the prediction of oocyte recovery and pre-implantation embryo quality. Hum Reprod 1996; 11: 2512–2517.CrossRefGoogle Scholar
Bhal, P. Pugh, N, Chui, DK, et al. The use of transvaginal power Doppler ultrasonography to evaluate the relationship between perifollicular vascularity and outcome of in-vitro fertilisation treatment cycles. Hum Reprod 1999; 14(4): 919–945.CrossRefGoogle ScholarPubMed
Campbell, S, Bourne, TH, Tan, SL, Collins, WP. Hysterosalpingo contrast sonography (HyCoSy) and its future role within the investigation of infertility in Europe. Ultrasound Obstet Gynecol 1994; 4(3): 245–253.CrossRefGoogle ScholarPubMed
Strandell, A, Bourne, T, Berg, C, et al. The assessment of endometrial pathology and tubal patency: a comparison between the use of ultrasonography and X-ray hysterosalpingography for the investigation of infertile patients. Ultrasound Obstet Gynecol 1999; 14(3): 200–204.CrossRefGoogle Scholar
Ghazeeri, G, Kutteh, W, Ke, R. Sonohysterography (SHG); a prospective study to determine patient acceptability of SHG over hysterosalpinography (HSG) in the assessment of uterine structural abnormalities and tubal patency. Fertil Steril 1974; 1 (Suppl): 234–235.Google Scholar
Litta, P, Cosmi, E, Saccardi, C, et al. Outpatient operative polypectomy using a 5 mm hysteroscope without anaesthesia and/or analgesia: advantages and limits. Eur J Obstet Gynecol Reprod Biol 2008; 139: 210–214.CrossRefGoogle ScholarPubMed
Kremer, C, Duffy, S, Moroney, M. Patient satisfaction with outpatient hysteroscopy versus day case hysteroscopy: randomised controlled trial. BMJ 2000; 320: 279–282.CrossRefGoogle ScholarPubMed
Floris, S, Piras, B, Orrù, M, et al. Efficacy of intravenous tramadol treatment for reducing pain during office diagnostic hysteroscopy. Fertil Steril 2007; 87: 147–151.CrossRefGoogle ScholarPubMed
Tam, WH, Yuen, PM. Use of diclofenac as an analgesic in outpatient hysteroscopy: a randomized, double-blind, placebo-controlled study. Fertil Steril 2001; 76(5): 1070–1072.CrossRefGoogle ScholarPubMed
Campo, R, Molinas, CR, Rombauts, L, et al. Prospective multicentre randomized controlled trial to evaluate factors influencing the success rate of office diagnostic hysteroscopy. Hum Reprod 2005; 20: 258–263.CrossRefGoogle ScholarPubMed
Rullo, S, Sorrenti, G, Marziali, M, et al. Office hysteroscopy: comparison of 2.7 and 4 mm hysteroscopes for acceptability, feasibility and diagnostic accuracy. J Reprod Med 2005; 50: 45–48.Google ScholarPubMed
Unfried, G, Wieser, F, Albrecht, A, et al. Flexible versus rigid endoscopes for outpatient hysteroscopy: a prospective randomized clinical trial. Hum Reprod 2001; 16: 168–171.CrossRefGoogle ScholarPubMed
Shankar, M, Davidson, A, Taub, N, Habiba, M. Randomised comparison of distension media for outpatient hysteroscopy. BJOG 2004; 111: 57–62.CrossRefGoogle ScholarPubMed
Cooper, NA, Smith, P, Khan, KS, Clark, TJ. A systematic review of the effect of the distension medium on pain during outpatient hysteroscopy. Fertil Steril 2011; 95: 264–271.CrossRefGoogle ScholarPubMed
Cooper, NA, Smith, P, Khan, KS, Clark, TJ. Does cervical preparation before outpatient hysteroscopy reduce women’s pain experience? A systematic review. BJOG 2011; 118(11): 1292–1301.CrossRefGoogle ScholarPubMed
Guida, M, Pellicano, M, Zullo, F, et al. Outpatient operative hysteroscopy with bipolar electrode: a prospective multicentre randomized study between local anaesthesia and conscious sedation. Hum Reprod 2003; 18: 840–843.CrossRefGoogle ScholarPubMed
Cooper, NA, Smith, P, Khan, KS, Clark, TJ. Vaginoscopic approach to outpatient hysteroscopy: a systematic review of the effect on pain. BJOG 2010; 117: 532–539. Erratum in: BJOG 2010; 117: 1440.CrossRefGoogle ScholarPubMed
References
PCOS consensus. The Rotterdam ESHRE/ASRM-Sponsored PCOS consensus workshop group. Revised 2003 consensus on diagnostic criteria and long-term health risks related to polycystic ovary syndrome (PCOS). Hum Reprod 2004; 19: 41–47.CrossRefGoogle Scholar
PCOS consensus. The Rotterdam ESHRE/ASRM-Sponsored PCOS consensus workshop group. Revised 2003 consensus on diagnostic criteria and long-term health risks related to polycystic ovary syndrome (PCOS). Fertil Steril 2004; 81: 19–25.CrossRefGoogle Scholar
Balen, AH, Dresner, M, Scott, EM, et al. Should obese women with polycystic ovary syndrome receive treatment for infertility? BMJ 2006; 332: 434–435.CrossRefGoogle ScholarPubMed
Nelson, SM, Fleming, RF. The preconceptual contraception paradigm: obesity and infertility. Hum Reprod 2007; 22: 912–915.CrossRefGoogle ScholarPubMed
Reaven, GM. The insulin resistance syndrome: definition and dietary approaches to treatment. Annu Rev Nutr 2005; 25: 391–406.CrossRefGoogle ScholarPubMed
Moran, LJ, Noakes, M, Clifton, PM, et al. Dietary composition in restoring reproductive and metabolic physiology in overweight women with PCOS. J Clin Endocrinol Metab 2003; 88: 812–819.CrossRefGoogle Scholar
Stamets, K, Taylor, DS, Kunselman, A, et al. A randomized trial of the effects of two types of short-term hypocaloric diets on weight loss in women with PCOS. Fertol Steril 2004; 81: 630–637.CrossRefGoogle Scholar
Crosignani, PG, Colombo, M, Vegetti, W, et al. Overweight and obese anovulatory patients with polycystic ovaries: parallel improvements in anthropometric indices, ovarian physiology and fertility rate induced by diet. Hum Reprod 2003; 18: 1928–1932.CrossRefGoogle ScholarPubMed
Wiksten-Almstromer, M, Hirschberg, AL, Hagenfeldt, K. Prospective follow-up of menstrual disorders in adolescence and prognostic factors. ACTA Obstet Gynecol Scan 2008; 87: 1162–1168.CrossRefGoogle ScholarPubMed
Beckers, NG, Platteau, P, Eijkemans, R, et al. The early luteal phase administration of estrogen and progesterone does not induce premature luteolysis in normo-ovulatory women. Eu J Endocrinol 2006; 155: 355–363.CrossRefGoogle Scholar
Pildes, RB. Induction of ovulation with clomiphene. Am J Obstet Gynecol 1965; 15: 466–479.CrossRefGoogle Scholar
Dehbashi, S, Vafaei, H, Persanezhad, M, et al. Time of initiation of clomiphene citrate and pregnancy rate in polycystic ovary syndrome. Int J Gynaecol Obstet 2006; 93: 44–48.CrossRefGoogle Scholar
Moll, E, Bossuyt, PM, Korevaar, JC, et al. Effect of clomiphene citrate plus metformin and clomiphene citrate plus placebo on induction of ovulation in women with newly diagnosed PCOS: randomised double-blind clinical trial. BMJ 2006; 332: 1485.CrossRefGoogle Scholar
Legro, RS, Barnhart, HX, Schlaff, WD, et al. Clomiphene, metformin, or both for Infertility in the PCOS. N Engl J Med 2007; 356: 551–566.CrossRefGoogle ScholarPubMed
Koustra, E, White, DM, Franks, S. Modern use of CC in induction of ovulation. Hum Reprod Update 1997; 3: 359–365.CrossRefGoogle Scholar
Imani, B, Eijkemans, MJ, te Velde, ER, et al. Predictors of patients remaining anovulatory during clomiphene citrate induction of ovulation in normogonadotropic oligoamenorrheic infertility. J Clin Endocrinol Metab 1998; 83: 2361–2365.Google ScholarPubMed
Rossing, MA, Daling, JR, Weiss, NS, et al. Ovarian tumors in a cohort of infertile women. N Engl J Med 1994; 33: 771–776.CrossRefGoogle Scholar
Homburg, R. Clomiphene citrate-end of an era? A mini review. Hum Reprod 2005; 20: 2043–2051.CrossRefGoogle Scholar
Roumen, FJ, Doesburg, WH, Rolland, R. Treatment of infertile women with a deficient postcoital test with two antiestrogens: clomiphene and tamoxifen. Fertility and Sterility 1984; 41: 237–243.CrossRefGoogle ScholarPubMed
Van Santbrink, EJ, Fauser, BC. Urinary follicle-stimulating hormone for normogonadotropic clomiphene-resistant anovulatory infertility: prospective, randomized comparison between low-dose step-up and step-down dose regimens. J Clin Endocrinol Metab 1997; 82: 3597–3602.Google ScholarPubMed
LaMarca, A, Morgante, G, Palumbo, M, et al. Insulin-lowering treatment reduces aromatase activity in response to follicle-stimulating hormone in women with PCOS. Fertil Steril 2002; 78: 1234–1239.CrossRefGoogle Scholar
Coffler, MS, Patel, K., Dahan, MH, et al. Enhanced granulosa cell responsiveness to FSH during insulin infusion in women with PCOS treated with pioglitazone. J Clin Endocrinol Metab 2003; 88: 5624–5631.CrossRefGoogle ScholarPubMed
Lord, JM, Flight, IH, Norman, RJ. Metformin in polycystic ovary syndrome: systematic review and meta-analysis. BMJ 2003; 327: 951–953.CrossRefGoogle ScholarPubMed
Legro, RS, Zaino, RJ, Demers, LM, et al. The effects of metformin and rosiglitazone, alone and in combination, on the ovary and endometrium in PCOS. Am J Obstet Gynecol 2007; 196: 402–410.CrossRefGoogle Scholar
Glueck, CJ, Goldenberg, N, Pranikoff, J, et al. Height, weight and motor-social development during the first 18 months of life in 126 infants born to 109 mothers with polycystic ovary syndrome who conceived on and continued metformin through pregnancy. Hum Reprod 2004; 19: 1323–1330.CrossRefGoogle ScholarPubMed
Garcia-Velasco, JA, Moreno, L, Pacheco, A, et al. The aromatase inhibitor letrozole increases the concentration of intraovarian androgens and improves in vitro fertilization outcome in low responder patients: a pilot study. Fertil Steril 2005; 84: 82–87.CrossRefGoogle ScholarPubMed
Bayar, U, Basaran, M, Kiran, S, et al. Use of an aromatase inhibitor in patients with polycystic ovary syndrome: a prospective randomized trial. Fertil Steril 2006; 86: 1447–1451.CrossRefGoogle ScholarPubMed
Tulandi, T, Martin, J, Al-Fadhli, R, et al. Congenital malformations among 911 newborns conceived after infertility treatment with letrozole or clomiphene citrate. Fertil Steril 2006; 85: 1761–1765.CrossRefGoogle ScholarPubMed
Bayram, N, van Wely, M, van Der Veen, F. Recombinant FSH versus urinary gonadotrophins or recombinant FSH for ovulation induction in subfertility associated with polycystic ovary syndrome. Cochrane Database Syst Rev 2001; 2:CD002121.Google Scholar
Mulders, AG, Eijkemans, MJ, Imani, B, et al. Prediction of chances for success or complications in gonadotrophin ovulation induction in normogonadotrophic anovulatory infertility. Reprod BioMed Onl 2003; 7: 48–56.Google ScholarPubMed
Zawadski, JK, Dunaif, A. Diagnostic criteria for polycystic ovary syndrome: towards a rational approach. In: Dunaif, A, Givens, JR, Haseltine, F, eds. Polycystic Ovary Syndrome. Boston: Blackwell Scientific, 1992: 377–384.Google Scholar
Azziz, R, Carmina, E, Dewailly, D, et al. Position statement: criteria for defining PCOS as a predominantly hyperandrogenic syndrome: an androgen excess society guideline. J Clin Endocrinol Metab 2006; 91: 4237–4245.CrossRefGoogle ScholarPubMed
Rizk, B, Aboulghar, M. Modern management of ovarian hyperstimulation syndrome. Hum Reprod 1991; 6: 1082–1087.CrossRefGoogle ScholarPubMed
Rizk, B, Smitz, J. Ovarian hyperstimulation syndrome after superovulation for IVF and related procedures. Hum Reprod 1992; 7: 320–327.CrossRefGoogle ScholarPubMed
Rabau, E, Serr, DM, David, A, et al. Human menopausal gonadotrophin for anovulation and sterility. Am J Gynecol 1967; 98: 92–98.CrossRefGoogle Scholar
Rizk, B, Aboulghar, MA. Classification, pathophysiology and management of ovarian hyperstimulation syndrome. In: Brinsden, P, ed. A Textbook of In-vitro Fertilization and Assisted Reproduction, Second Edition. Carnforth-Lancs, UK: The Parthenon Publishing Group, 1999: 131–155.Google Scholar
Rizk, B. Ovarian hyperstimulation syndrome: epidemiology, pathophysiology. In: Prevention and Management. Cambridge: Cambridge University Press, 2006.Google Scholar
Rizk, B, Aboulghar, MA, Smitz, J, RonEl, R. The role of vascular endothelia growth factor and interleukins in the pathogenesis pf severe ovarian hyperstimulation syndrome. Hum Reprod Update 1997; 3: 255–266.CrossRefGoogle Scholar
Rizk, B. Complications of ovulation induction II Ovarian hyperstimulation syndrome. In Dickey, RP, Brinsden, PR, Pyrzak, R, eds. Manual of Intrauteine Insemination and Ovulation Induction. Cambridge: Cambridge University Press, 2010: 152–160.Google Scholar
Rizk, B, Aboulghar, M. Ovarian hyperstimulation syndrome. In: Rizk, B, Aboulghar, M, eds. Ovarian Stimulation. Cambridge: Cambridge University Press, 2011: 111–137.Google Scholar
Mathur, RS, Akande, AV, Keay, SD, et al. Distinction between early and late ovarian hyperstimulation syndrome. Fertil Steril 2000; 73: 901–907.CrossRefGoogle ScholarPubMed
Lyons, CA, Wheeler, CA, Frishman, GN, et al. Early and late presentation of the ovarian hyperstimulation syndrome: two distinct entities with different risk factors. Hum Reprod 1994; 9: 792–799.CrossRefGoogle ScholarPubMed
Rizk, B, Doyle, P, Tan, SL, et al. Perinatal outcome and congenital malformations in in-vitro fertilizatioin babies from the Bourn-Hallam group. Human Reprod 1991; 6(9): 1259–1264.CrossRefGoogle Scholar
Tan, SL, Doyle, P, Campbell, S, et al. Obstetric outcome of in-vitro fertilization pregnancies compared to naturally conceived pregnancies. Am J Obstet and Gynecol 1992; 167(3): 778–784.CrossRefGoogle Scholar
Hole, J, Porter, KB, Taylor, SK, et al. Multiple pregnancy following IVF. In: Rizk, B, ed. Ultrasonography in Reproductive Medicine and Infertility. Cambridge: Cambridge University Press, 2010: 291–296.CrossRefGoogle Scholar
Jauniaux, ERM, Rizk, B. Pregnancy After Assisted Reproductive Technology. Cambridge: Cambridge University Press, 2011: 1–3.Google Scholar
References
Stein, IF, Leventhal, ML. Amenorrhea associated with bilateral polycystic ovaries. Am J Obstet Gynecol 1935;29:181.CrossRefGoogle Scholar
Rotterdam ESHRE/ASRM-Sponsored PCOS Consensus Workshop Group. Revised 2003 consensus on diagnostic criteria and long-term health risks related to polycystic ovary syndrome. Fertil Steril 2004 Jan;81(1):19–25.CrossRefGoogle Scholar
Balen, AH, Laven, JS, Tan, SL, Dewailly, D. Ultrasound assessment of the polycystic ovary: international consensus definitions. Hum Reprod Update 2003 Nov–Dec;9(6):505–14.CrossRefGoogle ScholarPubMed
Azziz, R, et al. for the Androgen Excess Society. Positions statement: criteria for defining polycystic ovary syndrome as a predominantly hyperandrogenic syndrome: an Androgen Excess Society guideline. J Clin Endocrinol Metab 2006 Nov;91(11):4237–45.CrossRefGoogle ScholarPubMed
Knochenhauer ES1, Key, TJ, Kahsar-Miller, M, et al. Prevalence of the polycystic ovary syndrome in unselected black and white women of the southeastern United States: a prospective study. J Clin Endocrinol Metab 1998 Sep;83(9):3078–82.Google Scholar
Li, R, Zhang, Q, Yang, D, et al. Prevalence of polycystic ovary syndrome in women in China: a large community-based study. Hum Reprod 2013 Sep;28(9):2562–9.CrossRefGoogle Scholar
Ezeh, U, Yildiz, BO, Azziz, R. Referral bias in defining the phenotype and prevalence of obesity in polycystic ovary syndrome. J Clin Endocrinol Metabol 2013 Jun;98(6):E1088–96.CrossRefGoogle ScholarPubMed
Okoroh, EM, Hooper, WC, Atrash, HK, et al. Prevalence of polycystic ovary syndrome among the privately insured, United States, 2003–2008. Am J Obstet Gynecol 2012 Oct;207(4):299.e1–7.CrossRefGoogle ScholarPubMed
Speroff, L, Fritz, MA. Clinical Gynecologic Endocrinology and Infertility, 7th edition. Philadelphia: Lippincott Williams & Wilkins, 2005; chapter 6, pp 187–231.Google Scholar
Speroff, L, Fritz, MA. Clinical Gynecologic Endocrinology and Infertility, 7th edition. Philadelphia: Lippincott Williams & Wilkins, 2005; chapter 12, pp 465–98.Google Scholar
Nestler, JE, Powers, LP, Matt, DW, et al. A direct effect of hyperinsulinemia on serum sex hormone-binding globulin levels in obese women with the polycystic ovary syndrome. J Clin Endocrinol Metab 1991 Jan;72(1):83–9.CrossRefGoogle ScholarPubMed
Dunaif, A, Green, G, Futterweit, W, Dobrjansky, A. Suppression of hyperandrogenism does not improve peripheral or hepatic insulin resistance in the polycystic ovary syndrome. J Clin Endocrinol Metab 1990 Mar;70(3):699–704.CrossRefGoogle ScholarPubMed
Quinn, M, Shinkai, K, Pasch, L, et al. Prevalence of androgenic alopecia in patients with polycystic ovary syndrome and characterization of associated clinical and biochemical features. Fertility Steril. 2014 Apr;101(4):1129–34.CrossRefGoogle ScholarPubMed
Grundy, SM, Cleeman, JI, Daniels, SR, et al. Diagnosis and management of the metabolic syndrome: an American Heart Association/National Heart, Lung, and Blood Institute Scientific Statement. Circulation 2005 Oct 25;112(17):2735–52.Google ScholarPubMed
Ehrmann, DA, Liljenquist, DR, Kasza, K, et al. Prevalence and predictors of the metabolic syndrome in women with polycystic ovary syndrome. J Clin Endocrinol Metab 2006 Jan;91(1):48–53.CrossRefGoogle ScholarPubMed
Karaca, Z, Acmaz, B, Acmaz, G, et al. Routine screening for Cushing’s syndrome is not required in patients presenting with hirsutism. Eur J Endocrinol 2013 Mar;168(3):379–84.CrossRefGoogle Scholar
Yildiz, BO. Assessment, diagnosis and treatment of a patient with hirsutism. Nat Clin Pract Endoc 2008;4:294–300.CrossRefGoogle ScholarPubMed
Wang, S, Alvero, R. Racial and ethnic differences in physiology and clinical symptoms of polycystic ovary syndrome. [Review] Semin Reprod Med 2013 Sep;31(5):365–9.Google ScholarPubMed
Clayton, RN, Ogden, V, Hodgkinson, J, et al. How common are polycystic ovaries in normal women and what is their significance for the fertility of the population? Clin Endocrinol 1992 Aug;37(2):127–34.CrossRefGoogle ScholarPubMed
Robinson, S, Rodin, DA, Deacon, A, et al. Which hormone tests for the diagnosis of polycystic ovary syndrome? Br J Obstet Gynaecol 1992 Mar;99(3):232–8.CrossRefGoogle ScholarPubMed
Morgante, G, Musacchio, MC, Orvieto, R, et al. Alterations in thyroid function among the different polycystic ovary syndrome phenotypes. Gynecol Endocrinol 2013 Nov;29(11):967–9.CrossRefGoogle ScholarPubMed
Eilertsen, TB, Vanky, E, Carlsen, SM. Anti-mullerian hormone in the diagnosis of polycystic ovary syndrome: can morphologic description be replaced? Hum Reprod 2012 Aug;27(8):2494–502.CrossRefGoogle ScholarPubMed
Celik, C, Tasdemir, N, Abali, R, et al. Progression to impaired glucose tolerance or type 2 diabetes mellitus in polycystic ovary syndrome: a controlled follow-up study. Fertil Steril 2014 Apr;101(4):1123–8.CrossRefGoogle ScholarPubMed
Legro, RS, Kunselman, AR, Dodson, WC, Dunaif, A, Prevalence and predictors of risk for type 2 diabetes mellitus and impaired glucose tolerance in polycystic ovary syndrome: a prospective, controlled study in 254 affected women. J Clin Endocrinol Metab 1999 Jan;84(1):165–9.Google ScholarPubMed
Shi, Y, Cui, Y, Sun, X, et al. Hypertension in women with polycystic ovary syndrome: prevalence and associated cardiovascular risk factors. Eur J Obstet Gynecol Reprod Biol 2014 Feb;173:66–70.CrossRefGoogle ScholarPubMed
Legro, RS, Kunselman, AR, Dunaif, A. Prevalence and predictors of dyslipidemia in women with polycystic ovary syndrome. Am J Med 2001 Dec 1;111(8):607–13.CrossRefGoogle ScholarPubMed
Mani, H, Levy, MJ, Davies, MJ, et al. Diabetes and cardiovascular events in women with polycystic ovary syndrome: a 20-year retrospective cohort study. Clin Endocrinol 2013 Jun;78(6):926–34.CrossRefGoogle ScholarPubMed
Guzick, DS, Talbott, EO, Sutton-Tyrrell, K, et al. Carotid atherosclerosis in women with polycystic ovary syndrome: initial results from a case-control study. Am J Obstet Gynecol 1996 Apr;174(4):1224–9.CrossRefGoogle ScholarPubMed
Setji, TL, Holland, ND, Sanders, LL, et al. Nonalcoholic steatohepatitis and nonalcoholic fatty liver disease in young women with polycystic ovary syndrome. J Clin Endocrinol Metab 2006 May;91(5):1741–7.CrossRefGoogle ScholarPubMed
Sahingoz, M, Uguz, F, Gezginc, K, Korucu, DG. Axis I and Axis II diagnoses in women with PCOS. Gen Hospit Psychiat 2013 Sep–Oct;35(5):508–11.Google ScholarPubMed
Milsom, SR, Nair, SM, Ogilvie, CM, et al. Polycystic ovary syndrome and depression in New Zealand adolescents. J Pediat Adolesc Gynecol 2013 Jun;26(3):142–7.CrossRefGoogle ScholarPubMed
Boomsma, CM, Eijkemans, MJ, Hughes, EG, et al. A meta-analysis of pregnancy outcomes in women with polycystic ovary syndrome. Hum Reprod Update 2006 Nov–Dec;12(6):673–83.CrossRefGoogle ScholarPubMed
Rai, R, Backos, M, Rushworth, F, Regan, L. Polycystic ovaries and recurrent miscarriage – a reappraisal. Hum Reprod 2000;15(3):612–15.CrossRefGoogle ScholarPubMed
Grigorescu, V, Zhang, Y, Kissin, DM, et al. Maternal characteristics and pregnancy outcomes after assisted reproductive technology by infertility diagnosis: ovulatory dysfunction versus tubal obstruction. Fertil Steril 2014 Apr;101(4):1019–25.CrossRefGoogle ScholarPubMed
Knowler, WC, et al. for the Diabetes Prevention Program Research Group. Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin. N Engl J Med 2002 Feb 7;346(6):393–403.Google ScholarPubMed
Panidis, D, Tziomalos, K, Macut, D, et al. Age- and body mass index-related differences in the prevalence of metabolic syndrome in women with polycystic ovary syndrome. Gynecol Endocrinol 2013 Oct;29(10):926–30.CrossRefGoogle ScholarPubMed
Vessey, M, Painter, R. Oral contraceptive use and cancer. Findings in a large cohort study, 1968–2004. Br J Cancer 2006;95:385–89.CrossRefGoogle Scholar
Verit, FF. The prevalence of metabolic syndrome in clomiphene citrate resistant polycystic ovary syndrome. Gynecol Endocrinol 2012 May;28(5):365–9.CrossRefGoogle ScholarPubMed
Creanga, AA, Bradly, HM, McCormick, C, Witkop, CT. Use of metformin in polycystic ovary syndrome. Obstet Gynecol 2008;111(4): 959–68.CrossRefGoogle ScholarPubMed
Mathur, R, Alexander, CJ, Yano, J, et al. Use of metformin in polycystic ovary syndrome. Am Obstet Gynecol 2008 Dec;199(6): 596–609.CrossRefGoogle ScholarPubMed
Nestler, JE, Jakubowicz, DJ, Evans, WS, Pasquali, R. Effects of metformin on spontaneous and clomiphene-induced ovulation in the polycystic ovary syndrome. New Engl J Med 1998 Jun 25;338(26):1876–80.CrossRefGoogle ScholarPubMed
Velazquez, E, Acosta, A, Mendoza, SG. Menstrual cyclicity after metformin therapy in polycystic ovary syndrome. Obstet Gynecol 1997 Sep;90(3):392–5.Google ScholarPubMed
Marshall, JC, Dunaif, A. Should all women with PCOS be treated for insulin resistance? Fertil Steril 2012 Jan;97(1):18–22.CrossRefGoogle ScholarPubMed
Palomba, S, Falbo, A, Zullo, F, Orio, F. Evidence based and potential benefits of metformin in the polycystic ovary syndrome: a comprehensive review. Endocr Rev 2013 July;30(1):1–50.CrossRefGoogle Scholar
Swiglo, BA, Cosma, M, Flynn, DN, et al. Clinical review: antiandrogens for the treatment of hirsutism: a systematic review and metaanalyses of randomized controlled trials. J Clin Endocrinol Metab 2008 Apr;93(4):1153–60.CrossRefGoogle ScholarPubMed
Pasquali, R, Gambineri, A. Glucose intolerance states in women with the polycystic ovary syndrome. [Review] J Endocrinol Invest 2013 Sep;36(8):648–53.Google ScholarPubMed
Lerchbaum, E, Schwetz, V, Giuliani, A, Obermayer-Pietsch, B. Assessment of glucose metabolism in polycystic ovary syndrome: HbA1c or fasting glucose compared with the oral glucose tolerance test as a screening method. Hum Reprod 2013 Sep;28(9):2537–44.CrossRefGoogle ScholarPubMed
References
Azziz, R. The evaluation and management of hirsutism. Obstet Gynecol. 2003;101:995–1007.Google ScholarPubMed
Hoffman, BL, Schorge, JO, Schaffer, JI, et al. Polycystic ovarian syndrome and hyperandrogenism. In: Hoffman, BL, Schorge, JO, Schaffer, JI, et al., eds. Williams Gynecology, 2nd ed. New York: McGraw-Hill; 2012. http://accessmedicine.mhmedical.com/content.aspx?bookid=399&Sectionid=41722306. Accessed August 26, 2014.Google Scholar
Emans, SJ. Androgen abnormalities in the adolescent girl. In: Emans, SJ, Laufer, MR, Goldstein, DP, eds. Pediatric and Adolescent Gynecology, 5th ed. Philadelphia: Lippincott Williams & Wilkins; 2005: pp 296–325.Google Scholar
Archer, JS, Chang, RJ. Hirsutism and acne in polycystic ovary syndrome. Best Pract Res Clin Obstet Gynaecol. 2004;18:737–54.CrossRefGoogle ScholarPubMed
Fritz, MA. Hirsutism. In: Fritz, MA, Speroff, L, eds. Clinical Gynecologic Endocrinology and Infertility, 10th ed. Philadelphia: Lippincott Williams & Wilkins; 2011: pp 533–66.Google Scholar
Hatch, R, Rosenfield, RL, Kim, MH, Tredway, D. Hirsutism: implications, etiology, and management. Am J Obstet Gynecol. 1981;1(140):815–30.Google Scholar
Cela, E, Robertson, C, Rush, K, et al. Prevalence of polycystic ovaries in women with androgenic alopecia. Eur J Endocrinol. 2003;149:439–42.CrossRefGoogle ScholarPubMed
Verkauf, BS, Von Thron, J, O’Brien, WF. Clitoral size in normal women. Obstet Gynecol. 1992;80:41–4.Google ScholarPubMed
Azziz, R, Zacur, HA. 21-Hydroxylase deficiency in female hyperandrogenism: screening and diagnosis. Clin Endocrinol Metab. 1989;69:577–84.CrossRefGoogle Scholar
Nieman, LK, Biller, BM, Findling, JW, et al. The diagnosis of Cushing’s syndrome: an Endocrine Society clinical practice guideline. J Clin Endocrinol Metab. 2008;93:1526–40.CrossRefGoogle ScholarPubMed
Borer, JG, Tan, PE, Diamond, DA. The spectrum of Sertoli cell tumors in children. Urol Clin North Am. 2000;27:529–41.CrossRefGoogle ScholarPubMed
Chivukula, M1, Hunt, J, Carter, G, et al. Recurrent gynandroblastoma of ovary-A case report: a molecular and immunohistochemical analysis. Int J Gynecol Pathol. 2007;26:30–3.CrossRefGoogle ScholarPubMed
Padilla, SL. Androgen-producing tumors in children and adolescents. Adolesc Pediatr Gynecol. 1989;2:135–42.CrossRefGoogle Scholar
Speiser, PW, White, PC. Congenital adrenal hyperplasia. N Engl J Med. 2003 Aug 21;349(8):776–88.CrossRefGoogle ScholarPubMed
Van der Spuy, ZM, le Roux, PA. Cyproterone acetate for hirsutism. Cochrane Database Syst Rev. 2003;4:CD001125.Google Scholar
Moghetti, P1, Castello, R, Magnani, CM, et al. Clinical and hormonal effects of the 5 alpha-reductase inhibitor finasteride in idiopathic hirsutism. J Clin Endocrinol Metab. 1994;79:1115–21.Google ScholarPubMed
Balfour, JA1, McClellan, K. Topical eflornithine. Am J Clin Dermatol. 2001;2:197–201CrossRefGoogle ScholarPubMed
Zaenglein, AL1, Thiboutot, DM. Expert committee recommendations for acne management. Pediatrics. 2006;118:1188–99.CrossRefGoogle ScholarPubMed
State-specific testing for congenital disorders, available at www.babysfirsttest.org/newborn-screening/states. Accessed August 26, 2014.Google Scholar
References
Molitch, ME. Prolactinoma. In: Melmed, S, ed. The Pituitary, 3rd ed. Waltham, MA: Academic Press; 2011: 475–531.Google Scholar
Melmed, S, Casanueva, FF, Hoffman, AR, et al. Diagnosis and treatment of hyperprolactinemia: an Endocrine Society clinical practice guideline. J Clin Endocrinol Metab. 2011 Feb;96(2):273–88.CrossRefGoogle ScholarPubMed
Waldstreicher, J, Duffy, JF, Brown, EN, et al. Gender differences in the temporal organization of prolactin (PRL) secretion: evidence for a sleep independent circadian rhythm of circulation PRL levels – a clinical research center study. J Clin Endocrinol Metab. 1996;81:1483–7.Google Scholar
Daly, AF, Rixhon, M, Adam, C, et al. High prevalence of pituitary adenomas: a cross-sectional study in the province of Liege, Belgium. J Clin Endocrinol Metab. 2006;91:4769–75.CrossRefGoogle ScholarPubMed
Fernandez, A, Karavitaki, N, Wass, JA. Prevalence of pituitary adenomas: a community-based, cross-sectional study in Banbury (Oxfordshire, UK). Clin Endocrinol (Oxf). 2010;72:377–82.CrossRefGoogle ScholarPubMed
Kars, M, Souverein, PC, Herings, RM, et al. Estimated age- and sex-specific incidence and prevalence of dopamine agonist-treated hyperprolactinemia. J Clin Endocrinol Metab. 2009;94:2729–34.CrossRefGoogle ScholarPubMed
Thirunavakkarasu, K, Dutta, P, Sridhar, S, et al. Macroprolactinemia in hyperprolactinemic infertile women. Endocrine. 2013 Dec;44(3):750–5.CrossRefGoogle ScholarPubMed
Molitch, ME, Reichlin, S. Hyperprolactinemic disorders. Dis Mon. 1982;28:1–58.CrossRefGoogle ScholarPubMed
Schlechte, J, Sherman, B, Halmi, N, et al. Prolactin secreting pituitary tumours in amenorrheic women: a comprehensive study. Endocr Rev. 1980;1:295–308.CrossRefGoogle ScholarPubMed
Lee, D, Oh, Y, Yoon, B, et al. Prevalence of hyperprolactinemia in adolescents and young women with menstruation related problems. Am J Obstet Gyneco. 2012;206:213 e1–5.CrossRefGoogle Scholar
Demura, R, Ono, M, Demura, H, et al. Prolactin directly inhibits basal as well as gonadotropin-stimulated secretion of progesterone and 17 beta-estradiol in the human ovary. J Clin Endocrinol Metab. 1982;54:1246–50.CrossRefGoogle ScholarPubMed
Prabhakar, VK, Davis, JR. Hyperprolactinaemia. Best Pract Res Clin Obstet Gynaecol. 2008 Apr;22(2):341–53.CrossRefGoogle ScholarPubMed
Sobrinho, LG. Emotional aspects of hyperprolactinaemia. Psychother Psychosom. 1998;67:133–9.CrossRefGoogle Scholar
Melen, O. Neuro-ophthalmologic features of pituitary tumors. Endocrinol Metab Clin North Am. 1987;16:585–608.CrossRefGoogle ScholarPubMed
Cottier, JP, Destrieux, C, Brunereau, L, et al. Cavernous sinus invasion by pituitary adenoma: MR imaging. Radiology. 2000;215:463–9.CrossRefGoogle ScholarPubMed
Shimon, MD, Bronstein, J, Shapiro, G, et al. Women with prolactinomas presented at the postmenopausal period. Endocrine. 2014;47(3):889–94. First online 8 April 2014.CrossRefGoogle ScholarPubMed
Maor, Y, Berezin, M. Hyperprolactinemia in postmenopausal women. Fertil Steril. 1997;67:693–6.CrossRefGoogle ScholarPubMed
Delgrange, E, Raverot, G, Bex, M, et al. Giant prolactinomas in women. Eur J Endocrinol. 2013 Nov 22;170(1):31–8.Google ScholarPubMed
Schlechte, J, el-Khoury, G, Kathol, M, Walkner, L. Forearm and vertebral bone mineral in treated and untreated hyperprolactinemic amenorrhea. J Clin Endocrinol Metab. 1987;64:1021–6.CrossRefGoogle ScholarPubMed
Jarrell, J, Franks, S, McInnes, R, et al. Breast examination does not elevate serum prolactin. Fertil Steril. 1980;33:49–51.CrossRefGoogle Scholar
Luef, G. Horrmonal alterations following seizures. Epilepsy Behav. 2010 Oct;19(2):131–3.CrossRefGoogle ScholarPubMed
Bracero, N, Zacur, HA, Polycystic ovary syndrome and hyperprolactinemia. Obstet Gynecol Clin North Am. 2001;28:77–84.CrossRefGoogle ScholarPubMed
Prosser, PR, Karam, JH, Townsend, JJ, Forsham, PH. Prolactin-secreting pituitary adenomas in multiple endocrine adenomatosis, type I. Ann Intern Med. 1979;91(1):41–4.CrossRefGoogle ScholarPubMed
Schlechte, J, Dolan, K, Sherman, B, et al. The natural history of untreated hyperprolactinemia: a prospective analysis. J Clin Endocrinol Metab. 1989;68:412–8.CrossRefGoogle ScholarPubMed
Sisam, DA, Sheehan, JP, Sheeler, LR. The natural history of untreated microprolactinomas. Fertil Steril. 1987;48:67–71.CrossRefGoogle ScholarPubMed
Jeffcoate, WJ, Pound, N, Sturrock, ND, Lambourne, J. Long-term follow-up of patients with hyperprolactinaemia. Clin Endocrinol (Oxf). 1996;45:299–303.CrossRefGoogle ScholarPubMed
Karunakaran, S, Page, RC, Wass, JA. The effect of the menopause on prolactin levels in patients with hyperprolactinaemia. Clin Endocrinol (Oxf). 2001;54:295–300.CrossRefGoogle ScholarPubMed
Sarwar, KN, Huda, MS, Van de Velde, V, et al. The prevalence and natural history of pituitary hemorrhage in prolactinoma. J Clin Endocrinol Metab. 2013 Jun;98(6):2362–7.CrossRefGoogle ScholarPubMed
DailyMed. Bromocriptine. Available at: http://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=93a0696b-b261-4262-9e06-f3180b419f8f. Accessed 8 July 2014.Google Scholar
Webster, J. A comparative review of the tolerability profiles of dopamine agonists in the treatment of hyperprolactinaemia and inhibition of lactation. Drug Saf. 1996;14:228–38.Google ScholarPubMed
Wass, JA, Thorner, MO, Besser, GM. Letter: digital vasospasm with bromocriptine. Lancet. 1976;1:1135.CrossRefGoogle ScholarPubMed
Turner, TH, Cookson, JC, Wass, JA, et al. Psychotic reactions during treatment of pituitary tumours with dopamine agonists. Br Med J (Clin Res Ed). 1984;289:1101–3.CrossRefGoogle ScholarPubMed
Molitch, ME, Elton, RL, Blackwell, RE, et al. Bromocriptine as primary therapy for prolactin-secreting macroadenomas: results of a prospective multicenter study. J Clin Endocrinol Metab. 1985;60:698–705.CrossRefGoogle ScholarPubMed
Wang, AT, Mullan, RJ, Lane, MA, et al. Treatment of hyperprolactinemia: a systematic review and meta-analysis. Syst Rev. 2012;1:33.CrossRefGoogle ScholarPubMed
DailyMed. Cabergoline. Available at: http://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=e563bf14-daca-9bfb-f324-1d243150528e. Accessed 8 July 2014.Google Scholar
Webster, J, Piscitelli, G, Polli, A, et al. The efficacy and tolerability of long-term cabergoline therapy in hyperprolactinaemic disorders: an open, uncontrolled, multicentre study: European Multicentre Cabergoline Study Group. Clin Endocrinol (Oxf). 1993 Sep;39(3):323–9.CrossRefGoogle ScholarPubMed
Colao, A, Di Sarno, A, Landi, ML, et al. Macroprolactinoma shrinkage during cabergoline treatment is greater in naive patients than in patients pretreated with other dopamine agonists: a prospective study in 110 patients. J Clin Endocrinol Metab. 2000;85:2247–52.Google ScholarPubMed
Delgrange, E, Daems, T, Verhelst, J, et al. Characterization of resistance to the prolactin-lowering effects of cabergoline in macroprolactinomas: a study in 122 patients. Eur J Endocrinol. 2009;160:747–52.CrossRefGoogle Scholar
Ono, M, Miki, N, Kawamata, T, et al. Prospective study of high-dose cabergoline treatment of prolactinomas in 150 patients. J Clin Endocrinol Metab. 2008;93:4721–7.CrossRefGoogle ScholarPubMed
Webster, J, Piscitelli, G, Polli, A, et al. A comparison of cabergoline and bromocriptine in the treatment of hyperprolactinemic amenorrhea: Cabergoline Comparative Study Group. N Engl J Med. 1994;331:904–9.CrossRefGoogle ScholarPubMed
Nunes, V, El Dib, R, Boguszewski, C, et al. Cabergoline versus bromocriptine in the treatment of hyperprolactinemia: a systematic review of randomized controlled trials and meta-analysis. Pituitary. 2011:14;3:259–65.Google Scholar
Zanettini, R, Antonini, A, Gatto, G, et al. Valvular heart disease and the use of dopamine agonists for Parkinson’s disease. N Engl J Med. 2007;356:39.CrossRefGoogle ScholarPubMed
Rasmussen, VG, Østergaard, K, Dupont, E, Poulsen, SH. The risk of valvular regurgitation in patients with Parkinson’s disease treated with dopamine receptor agonists. Mov Disord. 2011 Apr;26(5):801–6.CrossRefGoogle ScholarPubMed
Kars, M, Delgado, V, Holman, ER, et al. Aortic valve calcification and mild tricuspid regurgitation but no clinical heart disease after 8 years of dopamine agonist therapy for prolactinoma. J Clin Endocrinol Metab. 2008;93:3348–56.CrossRefGoogle ScholarPubMed
Colao, A, Galderisi, M, Di Sarno, A, et al. Increased prevalence of tricuspid regurgitation in patients with prolactinomas chronically treated with cabergoline. J Clin Endocrinol Metab. 2008;93:3777–84.CrossRefGoogle ScholarPubMed
Halperin, I, Aller, J, Varela, C, et al. No clinically significant valvular regurgitation in long-term cabergoline treatment for prolactinoma. Clin Endocrinol (Oxf). 2012 Aug;77(2):275–80.CrossRefGoogle ScholarPubMed
Tan, T, Cabrita, IZ, Hensman, D, et al. Assessment of cardiac valve dysfunction in patients receiving cabergoline treatment for hyperprolactinaemia. Clin Endocrinol (Oxf). 2010 Sep;73(3):369–74.CrossRefGoogle ScholarPubMed
Vallette, S, Serri, K, Rivera, J, et al. Long-term cabergoline therapy is not associated with valvular heart disease in patients with prolactinomas. Pituitary. 2009;12:153–7.CrossRefGoogle Scholar
Auriemma, RS, Pivonello, R, Perone, Y, et al. Safety of long-term treatment with cabergoline on cardiac valve disease in patients with prolactinomas. Eur J Endocrinol. 2013 Aug 28;169(3):359–66.CrossRefGoogle ScholarPubMed
Delgado, V, Biermasz, NR, van Thiel, SW, et al. Changes in heart valve structure and function in patients treated with dopamine agonists for prolactinomas, a 2-year follow-up study. Clin Endocrinol (Oxf). 2012 Jul;77(1):99–105.CrossRefGoogle ScholarPubMed
Colao, A, Di Sarno, A, Sarnacchiaro, F, et al. Prolactinomas resistant to standard dopamine agonists respond to chronic cabergoline treatment. J Clin Endocrinol Metab. 1997;82:876–83.Google ScholarPubMed
Biswas, M, Smith, J, Jadon, D, et al. Long-term remission following withdrawal of dopamine agonist therapy in subjects with microprolactinomas. Clin Endocrinol (Oxf). 2005;63:26–31.CrossRefGoogle ScholarPubMed
Colao, A, Di Sarno, A, Cappabianca, P, et al. Withdrawal of long-term cabergoline therapy for tumoral and nontumoral hyperprolactinemia. N Engl J Med. 2003;349:2023–33.CrossRefGoogle ScholarPubMed
Kharlip, J, Salvatori, R, Yenokyan, G, Wand, GS. Recurrence of hyperprolactinemia after withdrawal of long-term cabergoline therapy. J Clin Endocrinol Metab. 2009;94:2428–36.CrossRefGoogle ScholarPubMed
Anagnostis, P, Adamidou, F, Polyzos, SA, et al. Long term follow-up of patients with prolactinomas and outcome of dopamine agonist withdrawal: a single center experience. Pituitary. 2012 Mar;15(1):25–9.CrossRefGoogle ScholarPubMed
Moraes, AB, Silva, CM, Vieira Neto, L, et al. Giant prolactinomas: the therapeutic approach. Clin Endocrinol (Oxf). 2013 Oct;79(4):447–56.CrossRefGoogle ScholarPubMed
Wu, ZB, Su, ZP, Wu, JS, et al. Five years follow-up of invasive prolactinomas with special reference to the control of cavernous sinus invasion. Pituitary. 2008;11:63–70.CrossRefGoogle Scholar
Delgrange, E, Duprez, T, Maiter, D. Influence of parasellar extension of macroprolactinomas defined by magnetic resonance imaging on their responsiveness to dopamine agonist therapy. Clin Endocrinol (Oxf). 2006;64:456–62.CrossRefGoogle ScholarPubMed
Faria, MA, Tindall, GT. Transsphenoidal microsurgery for prolactin-secreting pituitary adenomas. J Neurosurg. 1982;56:33–43.CrossRefGoogle ScholarPubMed
Thomson, JA, Davies, DL, McLaren, EH, et al. Ten year follow up of microprolactinoma treated by transsphenoidal surgery. BMJ. 1994;309:1409–10.CrossRefGoogle ScholarPubMed
Ikeda, H, Watanabe, K, Tominaga, T, Yoshimoto, T. Transsphenoidal microsurgical results of female patients with prolactinomas. Clin Neurol Neurosurg. 2013 Sep;115(9):1621–5.CrossRefGoogle ScholarPubMed
Buchfelder, M, Schlaffer, S. Surgical treatment of pituitary tumors. Best Pract Res Clin Endocrinol Metab. 2009 Oct;23(5):677–92.CrossRefGoogle Scholar
Sun, DQ, Cheng, JJ, Frazier, JL, et al. Treatment of pituitary adenomas using radiosurgery and radiotherapy: a single center experience and review of literature. Neurosurg Rev. 2011;34:181–9.CrossRefGoogle Scholar
Rigg, LA, Lein, A, Yen, SS. Pattern of increase in circulating prolactin levels during human gestation. Am J Obstet Gynecol. 1977;129:454–6.CrossRefGoogle ScholarPubMed
Glezer, A, Bronstein, M. Prolactinomas, cabergoline and pregnancy. Endocrine. 2014;47:64–9.CrossRefGoogle ScholarPubMed
Krupp, P, Monka, C. Bromocriptine in pregnancy: safety aspects. Klin Wochenschr. 1987;65:823–7.CrossRefGoogle ScholarPubMed
Molitch, ME. Prolactinoma in pregnancy. Best Pract Res Clin Endocrinol Metab. 2011 Dec;25(6):885–96.CrossRefGoogle ScholarPubMed
Lebbe, M, Hubinont, C, Bernard, P, et al. Outcome of 100 pregnancies initiated under treatment with cabergoline in hyperprolactinaemic women. Clin Endocrinol. 2010;73:236–42.CrossRefGoogle ScholarPubMed
Webster, J. A comparative review of the tolerability profiles of dopamine agonists in the treatment of hyperprolactinaemia and inhibition of lactation. Drug Saf. 1996;14:228–38.Google ScholarPubMed
Colao, A, Abs, R, Barcena, DG, et al. Pregnancy outcomes following cabergoline treatment: extended results from a 12-year observational study. Clin Endocrinol (Oxf). 2008;68:66–71.CrossRefGoogle ScholarPubMed
Raymond, JP, Goldstein, E, Konopka, P, et al. Follow-up of children born of bromocriptine-treated mothers. Horm Res. 1985;22:239–46.CrossRefGoogle ScholarPubMed
Konopka, P, Raymond, JP, Merceron, RE, et al. Continuous administration of bromocriptine in the prevention of neurological complications in pregnant women with prolactinomas. Am J Obstet Gynecol. 1983;146:935–8.CrossRefGoogle ScholarPubMed
Hurault-Delarue, C, Montastruc, J-L, Beau, A-B, et al. Pregnancy outcome in women exposed to dopamine agonists during pregnancy: a pharmacoepidemiology study in EFEMERIS database. Arch Gynecol Obstet. 2014;23(6):586–94.Google Scholar
Domingue, ME, Devuyst, F, Alexopoulou, O, et al. Outcome of prolactinoma after pregnancy and lactation: a study of 73 patients. Clin Endocrinol (Oxf). 2014 May;80(5):642–8.CrossRefGoogle ScholarPubMed
TOXNET databases. LactMed: Cabergoline. Available at: http://toxnet.nlm.nih.gov/cgi-bin/sis/search2/r?dbs±lactmed:@or±%28@na±%22CABERGOLINE%22±%29. Accessed 8 July 2014.Google Scholar
TOXNET databases. LactMed: Bromocriptine. Available at: http://toxnet.nlm.nih.gov/cgi-bin/sis/search2/r?dbs±lactmed:@term±@na±Bromocriptine. Accessed 8 July 2014.Google Scholar
References
Harlow, SD, Gass, M, Hall, JE, et al. Executive summary of the Stages of Reproductive Aging Workshop + 10: addressing the unfinished agenda of staging reproductive aging. J Clin Endocrinol Metab 2012; 97:1159–68.CrossRefGoogle ScholarPubMed
Van Voorhis, BJ, Santoro, N, Harlow, S, et al. The relationship of bleeding patterns to daily reproductive hormones in women approaching menopause. Obstet Gynecol 2008; 112:101–8.CrossRefGoogle ScholarPubMed
Randolph, JF Jr, Sowers, M, Bondarenko, I, et al. The relationship of longitudinal change in reproductive hormones and vasomotor symptoms during the menopausal transition. J Clin Endocrinol Metab 2005; 90:6106–12.CrossRefGoogle ScholarPubMed
Broer, SL, Eijkemans, MJ, Scheffer, GJ, et al. Anti-mullerian hormone predicts menopause: a long-term follow-up study in normoovulatory women. J Clin Endocrinol Metab 2011; 96:2532–9.CrossRefGoogle ScholarPubMed
Broer, SL, Willem, B, Hendriks, D, et al. Then role of antimullerian hormone in prediction of outcome after IVF – comparison with the antral follicle count. Fert Steril 2009; 91:705–14.CrossRefGoogle ScholarPubMed
Burger, HG, Hale, GE, Dennerstein, L, Robertson, DM. Cycle and hormone changes during perimenopause: the key role of ovarian function. Menopause 2008; 15:603–12.Google ScholarPubMed
Hee, J, MacNaughton, J, Bangah, M, Burger, HG. Perimenopausal patterns of gonadotrophins, immunoreactive inhibin, oestradiol and progesterone. Maturitas 1993; 18:9–20.CrossRefGoogle Scholar
Ahmed Ebbiary, NA, Lenton, EA, Cooke, ID. Hypothalamic-pituitary ageing: progressive increase in FSH and LH concentrations throughout the reproductive life in regularly menstruating women. Clin Endocrin 1994; 41:199–206.CrossRefGoogle ScholarPubMed
Santoro, N, Brockwell, S, Johnston, J, et al. Helping midlife women predict the onset of the final menses: SWAN, the Study of Women’s Health across the Nation. Menopause 2007; 14:415–424.CrossRefGoogle ScholarPubMed
Luborsky, JL, Meyer, P, Sowers, MF, et al. Premature menopause in a multi-ethnic population study of the menopause transition. Hum Reprod; 18:199–206.CrossRefGoogle Scholar
Marret, H, Fauconnier, A, Chabbert-Buffet, N. Clinical practice guidelines on menorrhagia: management of abnormal uterine bleeding before menopause. Eur J Obstet Gynecol 2010; 152:133–7.CrossRefGoogle ScholarPubMed
Stearns, V, Ulmer, L, Lopez, JF, et al. Hot flushes. Lancet 2002; 360:1851–61.CrossRefGoogle ScholarPubMed
Kravitz, HM, Ganz, PA, Bromberger, J, et al. Sleep difficulty in women at midlife: a community survey of sleep and the menopausal transition. Menopause 2003; 10:19–28.Google ScholarPubMed
Nedrow, A, Miller, J, Walker, M, et al. Complementary and alternative therapies for the management of menopause-related symptoms: a systematic evidence review. Arch Intern Med 2006; 166:1453–65.CrossRefGoogle ScholarPubMed
Newton, KM, Reed, SD, LaCroix, AZ, et al. Treatment of vasomotor symptoms of menopause with black cohosh, multibotanicals, soy, hormone therapy, or placebo: a randomized trial. Ann Intern Med 2006; 145:869–79.CrossRefGoogle ScholarPubMed
Taylor, HS, Manson, JE. Update in hormone therapy use in menopause. J Clin Endocrinol Metab 2011; 96:255–64.CrossRefGoogle ScholarPubMed
Simon, J, Portman, DJ, Kaunitz, AM, et al. Low-dose paroxetine 7.5 mg for menopausal vasomotor symptoms: two randomized controlled trials. Menopause 2013; 20:1027–35.Google ScholarPubMed
Reddy, SY, Warner, H, Guttuso, T, et al. Gabapentin, estrogen, and placebo for treating hot flushes: A randomized controlled trial. Obstet Gynecol 2006; 108:41–8.CrossRefGoogle ScholarPubMed
Nagamani, M, Kelver, ME, Smith, ER. Treatment of menopausal hot flashes with transdermal administration of clonidine. Am J Obstet Gynecol 1987; 156:561–5.CrossRefGoogle ScholarPubMed
Bertelli, G, Venturini, M, Del Mastro, L, et al. Intramuscular depot medroxyprogesterone versus oral megestrol for the control of postmenopausal hot flashes in breast cancer patients: a randomized study. Ann Oncol 2002; 13:883–8.CrossRefGoogle ScholarPubMed
Loprinzi, CL, Michalak, JC, Quella, SK, et al. Megestrol acetate for the prevention of hot flashes. N Engl J Med 1994; 331:347–52.CrossRefGoogle ScholarPubMed
Studee, DW, Panay, N. Recommendations for the management of postmenopausal vaginal atrophy. Climacteric 2010; 13:509–22.Google Scholar
Suckling, J, Lethaby, A, Kennedy, R. Local oestrogen for vaginal atrophy in postmenopausal women. Cochrane Database Syst Rev 2003; 4:CD001500.Google Scholar
Weisberg, E, Ayton, R, Darling, G, et al. Endometrial and vaginal effects of low-dose estradiol delivered by vaginal ring or vaginal tablet. Climacteric 2005; 8:83–93.CrossRefGoogle ScholarPubMed
Simon, J, Nachtigall, L, Ulrich, LG, et al. Endometrial safety of ultra-low-dose estradiol vaginal tablets. Obstet Gynecol 2010; 116:876–83.CrossRefGoogle ScholarPubMed
Barlow, DH, Cardozo, LD, Francis, RM, et al. Urogenital ageing and its effect on sexual health in older British women. Br J Obstet Gynaecol 1997; 104:87–91.CrossRefGoogle ScholarPubMed
Cayan, F, Dilek, U, Pata, O, Dilek, S. Comparison of the effects of hormone therapy regimens, oral and vaginal estradiol, estradiol + drospirenone and tibolone, on sexual function in healthy postmenopausal women. J Sex Med 2008; 5:132–8.CrossRefGoogle ScholarPubMed
Shifren, JL, Braunstein, GD, Simon, JA. Transdermal testosterone treatment in women with impaired sexual function after oophorectomy. N Engl J Med 2000; 343:682–6.CrossRefGoogle ScholarPubMed
Somboonporn, W, Bell, RJ, Davis, SR. Testosterone for peri and postmenopausal women. Cochrane Database Syst Rev 2005 Oct 19; 4:CD004509.Google Scholar
Sarwer, DB, Durlak, JA. A field trial of the effectiveness of behavioral treatment for sexual dysfunctions. J Sex Marital Ther 1997; 23:87–97.CrossRefGoogle ScholarPubMed
Greendale, GA, Derby, CA, Maki, PM. Perimenopause and cognition. Obstet Gynecol Clin North Am 2011; 38:519–35.CrossRefGoogle ScholarPubMed
Shaywitz, SE, Shaywitz, BA, Pugh, KR, et al. Effect of estrogen on brain activation patterns in postmenopausal women during working memory tasks. JAMA 1999; 281:1197–202.CrossRefGoogle ScholarPubMed
Lethaby, A, Hogervorst, E, Richards, M, et al. Hormone replacement therapy for cognitive function in postmenopausal women. Cochrane Database Syst Rev 2008 Jan 23; 1:CD003122.Google Scholar
Rapp, SR, Espeland, MA, Shumaker, SA, et al. Effect of estrogen plus progestin on global cognitive function in postmenopausal women: the Women’s Health Initiative Memory Study: a randomized controlled trial. JAMA 2003; 289:2663–72.CrossRefGoogle ScholarPubMed
Avis, NE, Brambilla, D, McKinlay, SM, Vass, K. A longitudinal analysis of the association between menopause and depression. Results from the Massachusetts Women’s Health Study. Ann Epidemiol 1994; 4:214–20.CrossRefGoogle ScholarPubMed
Freeman, EW, Sammel, MD, Lin, H, Nelson, DB. Associations of hormones and menopausal status with depressed mood in women with no history of depression. Arch Gen Psychiatry 2006; 63:375–82.CrossRefGoogle ScholarPubMed
Recker, R, Lappe, J, Davies, K, Heaney, R. Characterization of perimenopausal bone loss: a prospective study. J Bone Miner Res 2000; 15:1965–73.CrossRefGoogle ScholarPubMed
Panula, J, Pihlajamäki, H, Mattila, VM, et al. Mortality and cause of death in hip fracture patients aged 65 or older: a population-based study. BMC Musculoskelet Disord 2011; 12:105.CrossRefGoogle ScholarPubMed
Rossouw, JE, Prentice, RL, Manson, JE, et al. Postmenopausal hormone therapy and risk of cardiovascular disease by age and years since menopause. JAMA 2007; 297:1465–77.CrossRefGoogle ScholarPubMed
Santen, RJ, Allred, DC, Ardoin, SP, et al. Postmenopausal hormone therapy: an Endocrine Society scientific statement. J Clin Endocrinol Metab 2010; 95:s1–s66.CrossRefGoogle ScholarPubMed
References
Vanderpump, MP, Tunbridge, WM, French, JM, et al. The incidence of thyroid disorders in the community: a twenty-year follow-up of the Whickham Survey. Clin Endocrinol (Oxf) 1995 Jul; 43(1): 55–68.CrossRefGoogle ScholarPubMed
Hollowell, JG, Staehling, NW, Flanders, WD, et al. Serum TSH, T4, and thyroid antibodies in the United States population (1988 to 1994): National Health and Nutrition Examination Survey (NHANES III). J Clin Endocrinol Metab 2002; 87: 489–499.CrossRefGoogle ScholarPubMed
Canaris, GJ, Manowitz, NR, Mayor, G, Ridgway, EC. The Colorado thyroid disease prevalence study. Arch Intern Med 2000; 160: 526–534.CrossRefGoogle ScholarPubMed
Baskin, HJ, Cobin, RH, Duick, DS, et al. for the American Association of Clinical Endocrinologists. American Association of Clinical Endocrinologists medical guidelines for clinical practice for the evaluation and treatment of hyperthyroidism and hypothyroidism. Endocr Pract 2002; 8: 457–469.CrossRefGoogle Scholar
Glinoer, D, de Nayer, P, Bourdoux, P, et al. Regulation of maternal thyroid during pregnancy. J Clin Endocrinol Metab 1990; 71: 276–287.CrossRefGoogle ScholarPubMed
ACOG. Subclinical hypothyroidism in pregnancy. Committee Opinion 381. October 2007, (reaffirmed 2012).Google Scholar
Burch, HB, Wartofsky, L. Life-threatening thyrotoxicosis – thyroid storm. Endocrinol Metab Clin North Am June 1993; 22 (2): 263–277.CrossRefGoogle ScholarPubMed
Franklyn, JA. The management of hyperthyroidism. New Engl J Med 1994; 330: 1731–1738.Google ScholarPubMed
Sawin, CT, Geller, A, Wolf, PA, et al. Low serum thyrotropin concentrations as a risk factor for atrial fibrillation in older persons. New Engl J Med 1994; 331: 1249–1252.CrossRefGoogle ScholarPubMed
Klubo-Gwiezdzinska, J, Wartofsky, L. Thyroid emergencies. Med Clin North Am 2012 March; 96(2): 385–403.CrossRefGoogle ScholarPubMed
Hackmon, R, Blichowski, M, Koren, G. The safety of methimazole and propylthiouracil in pregnancy: a systematic review. J Obstet Gynaecol Can 2012; 34(11): 1077–1086.CrossRefGoogle ScholarPubMed
Tan, JY, Loh, KC, Yeo, GS, Chee, YC. Transient hyperthyroidism of hyperemesis gravidarum. BJOG. 2002 Jun; 109(6): 683–688.CrossRefGoogle ScholarPubMed
Dozeman, R, Kaiser, FE, Cass, O, Pries, J. Hyperthyroidism appearing as hyperemesis gravidarum. Arch Intern Med 1983; 143(11): 2202–2203.CrossRefGoogle ScholarPubMed
Kristjansdottir, HL, Bodvarsdottir, SP, Sigurjonsdottir, HA. Sheehan’s syndrome in modern times: a nationwide retrospective study in Iceland. Eur J Endocrinol 2011 Mar; 164(3): 349–354.CrossRefGoogle ScholarPubMed
Zargar, AH, Singh, B, Laway, BA, et al. Epidemiologic aspects of postpartum pituitary hypofunction (Sheehan’s syndrome). Fertil Steril 2005; 84: 523–528.CrossRefGoogle ScholarPubMed
Gei-Guardia, O, Soto-Herrera, E, Gei-Brealey, A, Chen-Ku, CH. Sheehan syndrome in Costa Rica: clinical experience with 60 cases. Endocr Pract 2011 May–Jun; 17(3): 337–344.CrossRefGoogle ScholarPubMed
Tessnow, AH, Wilson, JD. The changing face of Sheehan’s syndrome. Am J Med Sci 2010 Nov; 340(5): 402–406.CrossRefGoogle ScholarPubMed
Sheehan, HL, Davis, JC. Post-partum Hypopituitarism. Springfield, IL: Charles C. Thomas, 1982.Google Scholar
Skałba, P1, Guz, M. Hypogonadotropic hypogonadism in women. Endokrynol Pol. 2011; 62(6): 560–567.Google ScholarPubMed
Silveira, LF, Latronico, AC. Approach to the patient with hypogonadotropic hypogonadism. J Clin Endocrinol Metab 2013; 98(5): 1781–1788.CrossRefGoogle Scholar
Burdelski, M, Nolkemper, D, Ganschow, R, et al. Liver transplantation in children: long-term outcome and quality of life. Eur J Pediatr Dec 1999; 158(Suppl 2): S34–S42.CrossRefGoogle ScholarPubMed
Bartosh, SM, Thomas, SE, Sutton, MM, et al. Linear growth after pediatric liver transplantation. J Pediatr Nov 1999; 135(5): 624–631.CrossRefGoogle ScholarPubMed
Wong, H. Management of diabetes insipidus. J Mich Pharmacist 1985 Feb; 23: 4–5, 25–27.Google Scholar
Ziai, F. Walter, R. Rosenthal, IM. Treatment of central diabetes insipidus in adults and children with desmopressin: synthetic analog of vasopressin. Arch Int Med 1978 Sept; 138: 1382–1385.CrossRefGoogle Scholar
Zaben, M. El Ghoul, W. Belli, A. Post-traumatic head injury pituitary dysfunction. [Review] Disabil Rehabil 2013; 35(6): 522–525.CrossRefGoogle ScholarPubMed
Gabbe, SG, Niebyl, JR, Simpson, JL. Obstetrics. In: Normal and Problem Pregnancies. Philadelphia: Elsevier, 2007: 1039.Google Scholar
Takayanagi, Y, Yoshida, M, Bielsky, IF, et al. Pervasive social deficits, but normal parturition, in oxytocin receptor-deficient mice. P Natl Acad Sci USA 2005; 102(44): 16096–16101.CrossRefGoogle ScholarPubMed
Young, WS 3rd, Shepard, E, Amico, J, et al. Deficiency in mouse oxytocin prevents milk ejection, but not fertility or parturition. J Neuroendocrinol 1996; 8(11): 847–853.CrossRefGoogle ScholarPubMed
Newell-Price, J, Bertagna, X, Grossman, AB, Nieman, LK. Cushing’s syndrome. Lancet 2006; 367(9522): 1605–1617.CrossRefGoogle ScholarPubMed
Newell-Price, J, Grossman, A. Diagnosis and management of Cushing’s syndrome. Lancet 1999 Jun 19; 353: 2087–2088.CrossRefGoogle ScholarPubMed
Eisenbarth, GS, Gottlieb, PA. Medical progress – autoimmune polyendocrine syndromes. New Engl J Med 2004; 350(20): 2068–2079.CrossRefGoogle Scholar
Baker, SJ, Wass, JA. Addison’s disease. BMJ 2009 July 2; 339: NIL_0007–NIL_0010.CrossRefGoogle ScholarPubMed
Callender, GG, Rich, TA, Perrier, ND. Multiple endocrine neoplasia syndromes. Surg Clin North Am. 2008 Aug; 88(4): 863–895.CrossRefGoogle ScholarPubMed
New, MI. Extensive clinical experience: nonclassical 21-hydroxylase deficiency. J Clin Endocrinol Metab 2006; 91(11): 4205–4214.CrossRefGoogle ScholarPubMed
Imperato-Mcginley, J, Peterson, RE, Gautier, T, Sturla, E. Androgens and the evolution of male-gender identity among male pseudohermaphrodites with 5α-reductase deficiency. New Engl J Med 1979; 300(22): 1233–1237.CrossRefGoogle ScholarPubMed
References
British Society for Paediatric & Adolescent Gynaecology. Available at: www.BritSPAG.org. Accessed 25 Feb 2015.Google Scholar
MacDougall, J, Creighton, SM, Wood, PL. Clinical networks in paediatric and adolescent gynaecology. BJOG 2010;117:131–133.CrossRefGoogle ScholarPubMed
Department of Health. Transition: getting it right for young people. 2006. Available at: webarchive.nationalarchives.gov.uk. Accessed 25 Feb 2015.Google Scholar
Department of Health. You’re welcome – quality criteria for young people friendly health services. 15 April 2011. Available at: www.gov.uk. Accessed 25 Feb 2015.Google Scholar
Fitzgerald, MJT, Fitzgerald, M. Human Embryology. London: Bailliere Tindall, 1994: 142–150.Google Scholar
Moore, KL, Persaud, TVN. The Developing Human, 8th Edition. Philadelphia: Elsevier, 2008: 243–284.Google Scholar
Webster, S, de Wreede, R. Embryology at a Glance, 1st Edition. Oxford: Wiley-Blackwell, 2012: 78–81. Companion website: www.wiley.com/go/embryology.Google Scholar
Toaff, ME, Lev-Toaff, AS, Toaff, R. Communicating uterine anomalies. Fertil Steril 1984;44:661–679.Google Scholar
Toaff, ME, Lev-Toaff, AS, Toaff, R. Communicating uteri: review and classification with introduction of two previously unreported types: Fertil Steril 1984;41(5):661–679.Google ScholarPubMed
Pandis, GK, Michala, L, Creighton, SM, Cutner, AS. Minimal access surgery in adolescent gynaecology. BJOG 2009;116:214–219.CrossRefGoogle ScholarPubMed
Griffin, JE, Edwards, C, Madden, JD, et al. Congenital absence of the vagina: the Mayer Rokitansky Kuster Hauser syndrome. Ann Intern Med 1976;85:224–236.CrossRefGoogle ScholarPubMed
Valappil, S, Chetan, U, Wood, N, Garden, A. Mayer-Rokitansky-Kuster-Hauser syndrome: diagnosis and management. Obstetrician & Gynaecologist. 2012;14:93–98.CrossRefGoogle Scholar
Brannstrom, M, Johannesson, L, Bokstrom, H, et al. Livebirth after uterus transplantation. Lancet 2015 Feb 12;385(9968):607–616. Published online October 6, 2014.CrossRefGoogle ScholarPubMed
Hall-Craggs, MA, Kirkham, A, Creighton, SM. Renal and urological abnormalities occurring with Mullerian anomalies. J Pediatr Urol 2013;9:27–32.CrossRefGoogle ScholarPubMed
Tseng, JJ, Ho, JY, Chen, WH, Chou, MM. Prenatal diagnosis of isolated fetal hydrocolpos secondary to imperforate hymen. J Chinese Med Assoc 2008 June;71(6):325.CrossRefGoogle ScholarPubMed
Edmonds, DK, Rose, GL. Outflow tract disorders of the female genital tract. Obstetrician & Gynaecologist 2013 Jan;15(1):11–17.CrossRefGoogle Scholar
Berra, M, Liao, LM, Creighton, SM, Conway, GS. Long-term health issues of women with XY karyotype. Maturitas 2010;65:172–178.CrossRefGoogle ScholarPubMed
Garden, AS, Topping, J. Paediatric & Adolescent Gynaecology for the MRCOG and Beyond. London: RCOG Press, 2001.Google Scholar
Creighton, SM, Liao, LM. Changing attitudes to sex assignment in intersex. BJU 2004;93:659–640.Google ScholarPubMed
Androgen Insensitivity Syndrome Support Group. Available at: aissg.org. Accessed 25 Feb 2015.Google Scholar
Congenital Adrenal Hyperplasia Support Group. Available at: livingwithcah.com. Accessed 25 Feb 2015.Google Scholar